CAR-T cell therapies have quickly evolved from promising idea into powerful cancer treatment, one that turns the body’s own defenses against disease. As researchers seek to extend and improve on their early successes, what can we expect next?
This report was produced for Eureka Therapeutics by Scientific American Custom Media, a division separate from the magazine’s board of editors.
CAR-T cell therapy uses a patient’s own cells to fight blood cancers. How a simple idea was terribly complex to realize.
Three innovative spins on CAR-T cell therapy promise more benefits and reduced damage from cellular cancer treatments.
For all their potential, CAR-T cell cancer therapies face significant obstacles. Bijan Nejadnik of Eureka Therapeutics explains one powerful method to overcome them.
Cheng Liu, CEO and Chairman of Eureka Therapeutics, discusses how to beat both cancer and viral infections with treatments inspired by nature.
The next iterations of T cell therapy will go after intracellular targets that until now have been unavailable.
